Fever and Neutropenia in Pediatric Patients with Cancer

Emergency Medicine Clinics of North America

Volumn 27, Issue 3, 2009, Pages 525-544

  Meckler, Garth ^a,b,c   Lindemulder, Susan ^b,c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Fever; Management; Neutropenia; Oncology; Pediatric

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANTACID AGENT; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; ASPARAGINASE; CARBAPENEM DERIVATIVE; CEPHALOSPORIN; CEPHALOSPORIN DERIVATIVE; CIDOFOVIR; COLONY STIMULATING FACTOR; CORTICOSTEROID; CYTARABINE; ETOPOSIDE; INFLUENZA VACCINE; METHOTREXATE; METICILLIN; OSELTAMIVIR; PALIVIZUMAB; PYRROLE DERIVATIVE; RIBAVIRIN; STEROID; UNINDEXED DRUG; VANCOMYCIN; VIDARABINE; ZANAMIVIR;

ADAPTIVE IMMUNITY; ADENOVIRUS INFECTION; ANAEROBIC INFECTION; ANAMNESIS; ASPERGILLOSIS; BACTERIAL INFECTION; BODY TEMPERATURE MEASUREMENT; CANCER PATIENT; CANCER SURGERY; CELLULAR IMMUNITY; CHILDHOOD CANCER; CHILL; CLINICAL OBSERVATION; CLINICAL TRIAL; CORE TEMPERATURE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG FEVER; DRUG MEGADOSE; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; FEBRILE NEUTROPENIA; FEVER; GASTRITIS; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HUMAN; HUMORAL IMMUNITY; HYPOPHYSIS DISEASE; IMMUNOPATHOGENESIS; INFLUENZA; INNATE IMMUNITY; LABORATORY TEST; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORBIDITY; MORTALITY; MUCOSA INFLAMMATION; MYCOSIS; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NEUTROPHIL COUNT; NONHUMAN; PANCREATITIS; PATHOPHYSIOLOGY; PATIENT ASSESSMENT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTOZOAL INFECTION; REVIEW; RIGOR; RISK ASSESSMENT; RISK FACTOR; SEPSIS; SIDE EFFECT; SYMPTOM; UNSPECIFIED SIDE EFFECT; VANCOMYCIN RESISTANT ENTEROCOCCUS; VIRUS INFECTION; VITAL SIGN; VOMITING; WEIGHT GAIN;

EID: 67651151219     PISSN: 07338627     EISSN: 07338627     Source Type: Journal    
DOI: 10.1016/j.emc.2009.04.007     Document Type: Review

References (107)

1. Hughes W.T., Bodey G.P., Bow E.J., et al. Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34 (2002) 730-751
2. Cerutti A., and Rescigno M. The biology of intestinal immunoglobulin A responses. Immunity 28 6 (2008) 740-750
3. Schenk M., and Mueller C. The mucosal immune system at the gastrointestinal barrier. Best Pract Res Clin Gastroenterol 22 3 (2008) 391-409
4. Pastva A.M., Wright J.R., and Williams K.L. Immunomodulatory roles of surfactant proteins A and D: implications in lung disease. Proc Am Thorac Soc 4 3 (2007) 252-257
5. Hussain S. Role of surfactant protein A in the innate host defense and autoimmunity. Autoimmunity 37 2 (2004) 125-130
6. Sano H., and Kuroki Y. The lung collectins, SP-A and SP-D, modulate pulmonary innate immunity. Mol Immunol 42 3 (2005) 279-287
7. Bodey G.P., Buckley M., Sathe Y.S., et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64 2 (1966) 328-340
8. Pickering L.K., Anderson D.C., Choi S., et al. Leukocyte function in children with malignancies. Cancer 35 5 (1975) 1365-1371
9. McCormack R.T., Nelson R.D., Bloomfield C.D., et al. Neutrophil function in lymphoreticular malignancy. Cancer 44 3 (1979) 920-926
10. Baehner R.L., Neiburger R.G., Johnson D.E., et al. Transient bactericidal defect of peripheral blood phagocytes from children with acute lymphoblastic leukemia receiving craniospinal irradiation. N Engl J Med 289 23 (1973) 1209-1213
11. Hersh E.V., Gutterman J.U., and Mavligit G.M. Effect of haematological malignancies and their treatment on host defence factors. Clin Haematol 5 2 (1976) 425-448
12. Roilides E., Uhlig K., Venzon D., et al. Prevention of corticosteroid-induced suppression of human polymorphonuclear leukocyte-induced damage of Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun 61 11 (1993) 4870-4877
13. Berenguer J., Allende M.C., Lee J.W., et al. Pathogenesis of pulmonary aspergillosis. Granulocytopenia versus cyclosporine and methylprednisolone-induced immunosuppression. Am J Respir Crit Care Med 152 3 (1995) 1079-1086
14. Lionakis M.S., and Kontoyiannis D.P. Glucocorticoids and invasive fungal infections. Lancet 362 9398 (2003) 1828-1838
15. Mackall C.L., Fleisher T.A., Brown M.R., et al. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 332 3 (1995) 143-149
16. Fisher R.I., DeVita Jr. V.T., Bostick F., et al. Persistent immunologic abnormalities in long-term survivors of advanced Hodgkin's disease. Ann Intern Med 92 5 (1980) 595-599
17. Bakhshi S., Padmanjali K.S., and Arya L.S. Infections in childhood acute lymphoblastic leukemia: an analysis of 222 febrile neutropenic episodes. Pediatr Hematol Oncol 25 5 (2008) 385-392
18. Stabell N., Nordal E., Stensvold E., et al. Febrile neutropenia in children with cancer: a retrospective Norwegian multicentre study of clinical and microbiological outcome. Scand J Infect Dis 40 4 (2008) 301-307
19. Katsimpardi K., Papadakis V., Pangalis A., et al. Infections in a pediatric patient cohort with acute lymphoblastic leukemia during the entire course of treatment. Support Care Cancer 14 3 (2006) 277-284
20. Lai H.P., Hsueh P.R., Chen Y.C., et al. Bacteremia in hematological and oncological children with febrile neutropenia: experience in a tertiary medical center in Taiwan. J Microbiol Immunol Infect 36 3 (2003) 197-202
21. Mahmud S., Ghafoor T., Badsha S., et al. Bacterial infections in paediatric patients with chemotherapy induced neutropenia. J Pak Med Assoc 54 5 (2004) 237-243
22. Ariffin H., Navaratnam P., and Lin H.P. Surveillance study of bacteraemic episodes of febrile neutropenic children. Int J Clin Pract 56 4 (2002) 237-240
23. Castagnola E., Fontana V., Caviglia I., et al. A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation. Clin Infect Dis 45 10 (2007) 1296-1304
24. Mendes A.V., Sapolnik R., and Mendonca N. New guidelines for the clinical management of febrile neutropenia and sepsis in pediatric oncology patients. J Pediatr (Rio J) 83 2 Suppl (2007) S54-S63
25. Kern W.V. Risk assessment and treatment of low-risk patients with febrile neutropenia. Clin Infect Dis 42 4 (2006) 533-540
26. Viscoli C., and Castagnola E. Treatment of febrile neutropenia: what is new?. Curr Opin Infect Dis 15 4 (2002) 377-382
27. Orudjev E., and Lange B.J. Evolving concepts of management of febrile neutropenia in children with cancer. Med Pediatr Oncol 39 2 (2002) 77-85
28. Ramphal R., Grant R.M., Dzolganovski B., et al. Herpes simplex virus in febrile neutropenic children undergoing chemotherapy for cancer: a prospective cohort study. Pediatr Infect Dis J 26 8 (2007) 700-704
29. Uys R., Cotton M.F., Wessels G., et al. Viral isolates during febrile neutropaenia in children with cancer. J Trop Pediatr 46 1 (2000) 21-24
30. Hughes W.T., Price R.A., Kim H.K., et al. Pneumocystis carinii pneumonitis in children with malignancies. J Pediatr 82 3 (1973) 404-415
31. Hughes W.T., Kuhn S., Chaudhary S., et al. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 297 26 (1997) 1419-1426
32. Hughes W.T., Rivera G.K., Schell M.J., et al. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 316 26 (1987) 1627-1632
33. Lai H.P., Chen Y.C., Chang L.Y., et al. Invasive fungal infection in children with persistent febrile neutropenia. J Formos Med Assoc 104 3 (2005) 174-179
34. Santolaya M.E., Alvarez A.M., Becker A., et al. Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia, and fever. J Clin Oncol 19 14 (2001) 3415-3421
35. Santolaya M.E., Alvarez A.M., Aviles C.L., et al. Prospective evaluation of a model of prediction of invasive bacterial infection risk among children with cancer, fever and neutropenia. Clin Infect Dis 35 (2002) 678-683
36. Santolaya M.E., Alvarez A.M., Aviles C.L., et al. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever and neutropenia at low risk for invasive bacterial infection. J Clin Oncol 22 18 (2002) 3784-3789
37. Baorto E.P., Aquino V.M., Mullen C.A., et al. Clinical parameters associated with low bacteremia risk in 1100 pediatric oncology patients with fever and neutropenia. Cancer 92 4 (2001) 909-913
38. Hartel C., Deuster M., Lehrnbecher T., et al. Current approaches for risk stratification of infectious complications in pediatric oncology. [see comment]. Pediatr Blood Cancer 49 6 (2007) 767-773
39. Ammann R.A., Hirt A., Lüthy A.R., et al. Identification of children presenting with fever in chemotherapy-induced neutropenia at low risk for severe bacterial infection. Med Pediatr Oncol 41 5 (2003) 436-443
40. Klaassen R.J., Goodman T.R., Pham B., et al. "Low-risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol 18 5 (2000) 1012-1019
41. Kern W.V., Cometta A., DeBock R., et al. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N Engl J Med 341 5 (1999) 312-318
42. Freifeld A., Marchigiani D., Walsh T., et al. A double-blind comparison of empirical oral and IV antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 341 5 (1999) 305-311
43. Petrilli A.S., Dantas L.S., Campos M.C., et al. Oral ciprofloxacin versus intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low-risk pediatric oncology patients: randomized prospective trial. Med Pediatr Oncol 34 (2000) 87-91
44. Mullen C.A., Petropoulos D., Roberts W.M., et al. Outpatient treatment of fever and neutropenia for low-risk pediatric cancer patients. Cancer 86 1 (1999) 126-134
45. Pagnanini H., Gomez S., Ruvinsky S., et al. Outpatient, sequential, parenteral-oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: a single-center, randomized, controlled trial in Argentina. Cancer 97 7 (2003) 1775-1780
46. Aquino V.M., Herrera L., Sandler E.S., et al. Feasibility of oral ciprofloxacin for the outpatient management of febrile neutropenia in selected children with cancer. Cancer 88 7 (2000) 1710-1714
47. Korones D.N., Hussong M.R., and Gullace M.A. Routine chest radiography of children with cancer hospitalized for fever and neutropenia: is it really necessary?. Cancer 80 6 (1997) 1160-1164
48. Feusner J., Cohen R., O'Leary M., et al. Use of routine chest radiography in the evaluation of fever in neutropenic pediatric oncology patients. J Clin Oncol 6 11 (1988) 1699-1702
49. Katz J.A., Bash R., Rollins N., et al. The yield of routine chest radiography in children with cancer hospitalized for fever and neutropenia. Cancer 68 5 (1991) 940-943
50. Renoult E., Buteau C., Turgeon N., et al. Is routine chest radiography necessary for the initial evaluation of fever in neutropenic children with cancer?. Pediatr Blood Cancer 43 (2004) 224-228
51. Goldstein B., Giroir B., Randolph A., and International Consensus Conference on Pediatric Sepsis. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. [see comment]. Pediatr Crit Care Med 6 1 (2005) 2-8
52. Watson R.S., and Carcillo J.A. Scope and epidemiology of pediatric sepsis. Pediatr Crit Care Med 6 3 Suppl (2005) S3-S5
53. Burns J.P. Septic shock in the pediatric patient: pathogenesis and novel treatments. Pediatr Emerg Care 19 2 (2003) 112-115
54. Talan D.A., Moran G.J., and Abrahamian F.M. Severe sepsis and septic shock in the ED. Infect Dis Clin North Am 22 1 (2008) 1-31
55. Catenacci M.H., and King K. Severe sepsis and septic shock: improving outcomes in the ED. Emerg Med Clin North Am 26 3 (2008) 603-623
56. Walsh T.J., and Schimpff S.C. Antibiotic combinations for the empiric treatment of the febrile neutropenic patient. Swiss Med J 113 (1983) 58-63
57. Ariffin H., Arasu A., Mahfuzah M., et al. Single-day ceftriaxone plus amikacin versus thrice-daily ceftazidime plus amikacin as empirical treatment of febrile neutropenia in children with cancer. J Paediatr Child Health 37 1 (2001) 38-43
58. Takeuchi M., Tanizawa A., and Mayumi M. Piperacillin plus aztreonam for treatment of neutropenic fever. Pediatr Int 45 3 (2003) 307-310
59. Hamidah A., Lim Y.S., Zulkifli S.Z., et al. Cefepime plus amikacin as an initial empirical therapy for febrile neutropenia in paediatric cancer patients. Singapore Med J 48 7 (2007) 615-619
60. Pizzo P.A., Hathorn J.W., Hiemenz J.W., et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 315 9 (1986) 552-558
61. DePauw B., Deresinski S., Feld R., et al. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. Ann Intern Med 120 10 (1994) 834-844
62. The EORTC International Antimicrobial Therapy Cooperative Group. Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med 317 27 (1987) 1692-1698
63. Freifeld A., Walsh T., Marshall D., et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol 13 1 (1995) 165-176
64. Klastersky J.A. Use of imipenem as empirical treatment of febrile neutropenia. Int J Antimicrob Agents 21 (2003) 393-402
65. Duzova A., Kutluk T., Kanra G., et al. Monotherapy with meropenem versus combination therapy with piperacillin plus amikacin as empiric therapy for neutropenic fever in children with lymphoma and solid tumors. Turk J Pediatr 43 2 (2001) 105-109
66. Chuang Y.Y., Hung I.J., Yang C.P., et al. Cefepime versus ceftazidime as empiric monotherapy for fever and neutropenia in children with cancer. Pediatr Infect Dis J 21 3 (2002) 203-209
67. Pancharoen C., Mekmullica J., Buranachonapa J., et al. Efficacy and safety of meropenem as an empirical treatment for febrile neutropenia in children with cancer. J Med Assoc Thai 86 Suppl 2 (2003) S174-S178
68. Hung K.C., Chiu H.H., Tseng Y.C., et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empirical therapy for neutropenic fever in children with malignancy. J Microbiol Immunol Infect 36 4 (2003) 254-259
69. Muller J., Garami M., Constantin T., et al. Meropenem in the treatment of febrile neutropenic children. Pediatr Hematol Oncol 22 4 (2005) 277-284
70. Ariffin H., Ai C.L., Lee C.L., et al. Cefepime monotherapy for treatment of febrile neutropenia in children. J Paediatr Child Health 42 12 (2006) 781-784
71. Bruckner L.B., Korones D.N., Karnauchow T., et al. High incidence of penicillin resistance among α-hemolytic streptococci isolated from the blood of children with cancer. J Pediatr 140 1 (2002) 20-26
72. National Advisory Committee on, Immunization (NACI). Statement on influenza vaccination for the 2008-2009 season. An Advisory Committee Statement (ACS). Canada Communicable Disease Report 34 ACS-3 (2008) 1-46
73. Suzuki E., and Ichihara K. The course of fever following influenza virus infection in children treated with oseltamivir. J Med Virol 80 6 (2008) 1065-1071
74. Sugaya N., Tamura D., Yamazaki M., et al. Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children. [see comment]. Clin Infect Dis 47 3 (2008) 339-345
75. Kawai N., Ikematsu H., Iwaki N., et al. A comparison of the effectiveness of zanamivir and oseltamivir for the treatment of influenza A and B. J Infect 56 1 (2008) 51-57
76. Vu D., Peck A.J., Nichols W.G., et al. Safety and tolerability of oseltamivir prophylaxis in hematopoietic stem cell transplant recipients: a retrospective case-control study. Clin Infect Dis 45 2 (2007) 187-193
77. Barr C.E., Schulman K., Iacuzio D., et al. Effect of oseltamivir on the risk of pneumonia and use of health care services in children with clinically diagnosed influenza. Curr Med Res Opin 23 3 (2007) 523-531
78. Maxwell S.R. Tamiflu and neuropsychiatric disturbance in adolescents. [see comment]. BMJ 334 7606 (2007) 1232-1233
79. Hama R. Oseltamivir's adverse reactions: fifty sudden deaths may be related to central suppression. [comment]. BMJ 335 7610 (2007) 59
80. Fuyuno I. Tamiflu side effects come under scrutiny. Nature 446 7134 (2007) 358-359
81. Simon A., Schildgen O., Panning M., et al. Respiratory syncytial virus infection in patients with cancer: still more questions than answers. [comment]. Clin Infect Dis 46 12 (2008) 1933-1934 [author reply 1934-5]
82. El Saleeby C.M., Somes G.W., DeVincenzo J.P., et al. Risk factors for severe respiratory syncytial virus disease in children with cancer: the importance of lymphopenia and young age. Pediatrics 121 2 (2008) 235-243
83. Ventre K., and Randolph A.G. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst Rev 1 (2007) CD000181
84. Chavez-Bueno S., Mejías A., Merryman R.A., et al. Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients. Pediatr Infect Dis J 26 12 (2007) 1089-1093
85. Mendoza Sanchez M.C., Ruiz-Contreras J., Vivanco J.L., et al. Respiratory virus infections in children with cancer or HIV infection. J Pediatr Hematol Oncol 28 3 (2006) 154-159
86. Ventre K., and Randolph A. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst Rev 4 (2004) CD000181
87. Sivaprakasam P., Carr T.F., Coussons M., et al. Improved outcome from invasive adenovirus infection in pediatric patients after hemopoietic stem cell transplantation using intensive clinical surveillance and early intervention. J Pediatr Hematol Oncol 29 2 (2007) 81-85
88. Christensen M.S., Nielsen L.P., and Hasle H. Few but severe viral infections in children with cancer: a prospective RT-PCR and PCR-based 12-month study. Pediatr Blood Cancer 45 7 (2005) 945-951
89. Gavin P.J., and Katz B.Z. Intravenous ribavirin treatment for severe adenovirus disease in immunocompromised children. Pediatrics 110 1 Pt 1 (2002) e9
90. Bordigoni P., Carret A.S., Venard V., et al. Treatment of adenovirus infections in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 32 9 (2001) 1290-1297
91. Groll A., Gea-Banacloche J., Glasmacher A., et al. Clinical pharmacology of antifungal agents. Infect Dis Clin North Am 17 (2003) 159-191
92. Shoham S., and Walsh T.J. Strategies for use of lipid formulations of amphotericin B. Curr Treat Options Infect Dis 4 (2002) 535-547
93. Walth T.J., Seibel N.L., Arndt C., et al. Amphotericin B lipid complex in pediatric patients with invasive fungal infections. Pediatr Infect Dis J 18 (1999) 702-708
94. Wiley J., Seibel N.L., and Walsh T.J. Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections. Pediatr Infect Dis J 24 (2005) 167-174
95. Wingard J.R., White M.H., Anaissie E., et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 31 (2003) 1155-1163
96. Lee J.W., Seibel M.L., Amantea M.A., et al. Safety and pharmacokinetics of fluconazole in children with neoplastic diseases. J Pediatr 120 6 (1992) 987-993
97. Walth T.J., Karlsson M.O., Driscoll T., et al. Pharmacokinetics and safety of intravenous voriconazole in children after single and multiple dose administration. Antimicrob Agents Chemother 48 (2004) 2166-2172
98. Walsh T.J., Lutsar I., Driscoll T., et al. Voriconazole in the treatment of aspergillosis, scedosporiosis, and other invasive fungal infections in children. Pediatr Infect Dis J 21 (2002) 240-248
99. Walsh T.J., Pappas P., Winston D.J., et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346 (2002) 225-234
100. Franklin J.A., McCormick J., and Flynn P. Retrospective study of the safety of caspofungin in immunocompromised pediatric patients. Pediatr Infect Dis J 22 (2003) 747-749
101. Seibel N.L., Schwartz C., Arrieta A., et al. Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother 49 (2005) 3317-3324
102. Benjamin D.K., Driscoll T., Siebel N.L., et al. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother 50 2 (2006) 632-638
103. Gafter-Gvili A., Vidal L., Goldberg E., et al. Treatment of invasive candidal infections: systematic review and meta-analysis. Mayo Clin Proc 83 9 (2008) 1011-1021
104. Smith T.J., Khatcheressian J., Lyman G.H., et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24 19 (2006) 3187-3205
105. Sung L., Nathan P.C., Lange B., et al. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials. J Clin Oncol 22 16 (2004) 3350-3356
106. Oxkaynak M.F., Krailo M., Chen Z., et al. Randomized comparison of antibiotics with and without granulocyte colony-stinulating factor in children with chemotherapy-induced febrile neutropenia: a report from the Children's Oncology Group. Pediatr Blood Cancer 45 (2005) 274-280
107. Wong E.C.C., Perez-Albuerne E., Moscow J.A., et al. Transfusion management strategies: a survey of practicing pediatric hematology/oncology specialists. Pediatr Blood Cancer 44 (2005) 119-127